BiVACOR, founded in 2008, is a privately held medical technology company headquartered in Houston, Texas, with an international office in Brisbane, Australia. The company's core mission is to revolutionize the treatment of heart failure through innovative solutions. BiVACOR focuses on developing a Total Artificial Heart (TAH) designed to provide a long-term solution for patients with severe heart failure. Their market focus includes the United States and Europe, where heart failure affects over 11 million people.
Notable figures affiliated with BiVACOR include world-class engineers, medical specialists, and business executives who contribute to its groundbreaking advancements. The company has received significant investment, including $13 million to support clinical trials for their TAH. BiVACOR's key achievements include establishing a strong collaborative network both nationally and internationally, positioning itself as a leader in the artificial heart market. Their work has the potential to impact thousands of patients who could benefit from advanced heart failure treatments.